Objective To elucidate the expression and clinical significance of HSP90α in the tissue of human hepatocellular carcinoma. Methods Immunohistochemical method was used to detect the expression of HSP90α in human h...Objective To elucidate the expression and clinical significance of HSP90α in the tissue of human hepatocellular carcinoma. Methods Immunohistochemical method was used to detect the expression of HSP90α in human hepatocellular carcinoma tissue. Results The positive expression rates of HSP90α were 10%, 52.5%, 72.5% in normal liver tissues, adjacent noncancerous liver tissues and hepatocellular carcinoma tissues, respectively. A significantly higher distribution of HSP90α expression in HCC tissues compared with adjacent noncancerous liver tissues and normal liver tissues was observed (P<0.05). HSP90α was correlated to tumor differentiation and capsule (P<0.05) but not to tumor number (P>0.05). It was also correlated to prognosis of HCC. The mean tumor-free survival period of patients with HSP90 α-negative was 38.6 months while that of HSP90α-positive was 25.5 months (P<0.05). Conclusion HSP90α is overexpressed in human hepatocellular carcinoma and might be used as an indicator to judge the differentiation and prognosis of HCC.展开更多
文摘Objective To elucidate the expression and clinical significance of HSP90α in the tissue of human hepatocellular carcinoma. Methods Immunohistochemical method was used to detect the expression of HSP90α in human hepatocellular carcinoma tissue. Results The positive expression rates of HSP90α were 10%, 52.5%, 72.5% in normal liver tissues, adjacent noncancerous liver tissues and hepatocellular carcinoma tissues, respectively. A significantly higher distribution of HSP90α expression in HCC tissues compared with adjacent noncancerous liver tissues and normal liver tissues was observed (P<0.05). HSP90α was correlated to tumor differentiation and capsule (P<0.05) but not to tumor number (P>0.05). It was also correlated to prognosis of HCC. The mean tumor-free survival period of patients with HSP90 α-negative was 38.6 months while that of HSP90α-positive was 25.5 months (P<0.05). Conclusion HSP90α is overexpressed in human hepatocellular carcinoma and might be used as an indicator to judge the differentiation and prognosis of HCC.